干扰素β-1b对多发性硬化患者生活质量影响的1年随访

目的观察干扰素β-1b(IFNβ-1b)治疗复发缓解型多发性硬化(MS)患者的疗效并进行生活质量评估,进一步探索生活质量的相关因素。方法选择接受IFNB-1b治疗的MS患者13例,并于治疗后第1个月、3个月、6个月、9个月、12个月对患者进行随访,评估包括扩展的功能缺损状况(EDSS)评分、多发性硬化患者生活质量量表(MSQOL-54)及汉密尔顿焦虑抑郁量表(HAMA、HAMD)评分。结果经IFNB1b治疗的MS患者在第1、3、6、9、12个月随访时生活质量、EDSS、HAMA、HAMD评分与治疗前比较均无明显变化(P0.05)。治疗前生活质量中躯体功能、性功能及对性生活满意度与EDSS评分呈负相关(P值均0.05);情绪致角色受限、疼痛与病程呈正相关(P值均0.05);躯体功能、情绪状况、社会功能、性功能及对性生活满意度与HAMA评分呈负相关(P值均0.05);认知、应激与HAMD评分均呈负相关(P值均0.05)。躯体致角色受限、精力、健康认知、总体生活质量及健康变化与病程、EDSS、HAMA、HAMD各项无相关性,年龄与MSQOL-54无关(P值均0.05)。结论 IFNB-1b短期内可能对MS患者生活质量无明显影响,生活质量与患者的EDSS评分、焦虑抑郁症状相关。

Effects of interferon β-1b on quality of life in patients with multiple sclerosis: a one-year follow-up study

Objective To observe the effects of interferon β-1b （IFNβ-1b） on the quality of life （QOL） in patients with relapsing-remitting multiple sclerosis （MS） and to determine the influential factors for QOL. Methods Thirteen MS patients treated with IFNβ-1b were included in the study. The scores on Multiple Sclerosis Quality of Life-54 （ MSQOL-54 ）, Expanded Disability Status Scale （EDSS）, Hamilton Anxiety Scale （HAMA）, and Hamilton Depression Scale （HAMD） were determined at baseline and 1,3, 6, 9, and 12 months after treatment. Results The MS patients treated with IFNβ-1b showed no significant changes in QOL and EDSS, HAMA, and HAMD scores at 1,3, 6, 9, and 12 months after treatment （P 〉 0.05 for all）. Before treatment, patients＇ physical health, sexual function, and satisfaction with sexual life were negatively correlated with EDSS score （P 〈 0.05 for all） ; role limitation due to emotional problems and bodily pain were positively correlated with the course of disease （P 〈 0.05 for both） ; physical health, emotion- al status, social function, sexual function, and satisfaction with sexual life were negatively correlated with HAMA score （P 〈 0.05 for all） ; cognitive function and stress were negatively correlated with HAMD score （P 〈 0.05 for both）. Role limitation due to physical problems, energy, health perception, overall QOL, and change in health showed no correlations with the course of disease and EDSS, HAMA and HAMD scores （P 〉 0.05 for all）, and no correlation was found between age and QOL （ P 〉 0.05）. Conclusions IFN- β1b therapy may not have significant impact on QOL in MS patients in short time. QOL is correlated with EDSS score and anxiety and depressive symptoms.